Adipose-Derived Mesenchymal Stem Cell for Preventing Biliary Complications
Trial statusNot yet recruiting
Trial phasePhase 1
Trial typeInterventional
Biological sexAll
Age18-65
SponsorMayo Clinic
About this trial
The purpose of this study is to assess the safety of autologous Adipose-Derived Mesenchymal Stem Cell for use in End-Stage Liver Disease patients undergoing the creation of a duct-to-duct anastomosis during Living Donor Liver Transplantation.
Eligibility criteria
Qualifiers
Listed for liver transplantation
Non-pediatric patients with a planned LDLT
Ability to communicate with investigative staff
Competence to give written informed consent
Disqualifiers
Planned deceased donor liver transplantation
Uncontrolled / unresolved local or systemic infection
Body mass index > 40
Planned pancreaticoduodenectomy or sleeve gastrectomy
Trial design
Treatments tested in this trial
- Autologous adipose derived mesenchymal stromal cells (AMSC)
Treatment groups
20 Participants
are divided into 1 treatment groupSponsors and collaborators
Source ClinicalTrials.gov